Page last updated: 2024-11-08

alnespirone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alnespirone: S 20499 is the (+)-enantiomer; S 20500 is the (-)-enantiomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID178132
CHEMBL ID2104091
SCHEMBL ID114478
MeSH IDM0202983

Synonyms (11)

Synonym
alnespirone [inn]
(+)-(s)-n-(4-((5-methoxy-3-chromanyl)propylamino)butyl)-1,1-cyclopentanediacetimide
alnespirone
8-[4-[[(3s)-5-methoxy-3,4-dihydro-2h-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
34e28bm822 ,
unii-34e28bm822
138298-79-0
CHEMBL2104091
SCHEMBL114478
DTXSID30160560
(s)-8-(4-((5-methoxychroman-3-yl)(propyl)amino)butyl)-8-azaspiro[4.5]decane-7,9-dione

Research Excerpts

Effects

ExcerptReferenceRelevance
"Alnespirone (S 20499) has previously been described as a potential anxiolytic drug that acts by stimulation of 5-HT1A receptors. "( Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
Comoy, E; Lesourd, M; Protais, P, 1998
)
1.99

Treatment

ExcerptReferenceRelevance
"The treatment with alnespirone did not modify baseline 5-HText but significantly attenuated the ability of 0.3 mg/kg s.c."( Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain.
Artigas, F; Casanovas, JM; Mengod, G; VilarĂ³, MT, 1999
)
0.83

Dosage Studied

ExcerptRelevanceReference
" The dose-response and time-course effects on the secretion of oxytocin and vasopressin revealed that alnespirone stimulated oxytocin in a dose-dependent manner, but did not increase vasopressin secretion."( A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499).
Brownfield, MS; Levy, AD; Li, Q; Van de Kar, LD, 1998
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's22 (78.57)18.2507
2000's6 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.10 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]